• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Concept Life Sciences launches, acquires three companies in $100M deal

Concept Life Sciences launches, acquires three companies in $100M deal

July 14, 2014
CenterWatch Staff

Concept Life Sciences, a newly formed international scientific laboratory and consultancy business, has made three acquisitions with a combined enterprise value approaching $100 million, following backing from Equistone Partners Europe. Concept Life Sciences acquired Peakdale Molecular, Resource & Environmental Consultants (REC) and Scientific Analysis Laboratories (SAL), which operate a number of sites across the U.K. 

Headquartered in Manchester, the group currently is focused on laboratory-based analytical testing and complex chemistry synthesis, with a view to accelerate investment in biological sciences, cell-based ADME services, biostorage and stability testing. 

Executive Chairman Michael Fort and CEO Alan Morgan will lead the business, which has over 500 staff across 10 core locations. Equistone partner Steve O'Hare and investment director Andi Tomkinson both join the board as non-executive directors. 

O'Hare said, "We've worked closely with the management team to develop the new group, whilst simultaneously making the foundation acquisitions, which have given entry into high-growth markets. The company has established a strong presence nationally and created a platform to target international growth and expand its service offering to existing clients. We look forward to developing the business further through the execution of its buy-and-build strategy."

Morgan said, "The acquisitions are the first steps in building a comprehensive platform of services for our clients requiring science-based innovative solutions. Our objective is to expand our capacity across a broad range of services adjacent to our current capabilities in life, food and environmental sciences."

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing